What is the significance of a negative Positron Emission Tomography (PET) scan result for a pulmonary nodule?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

A PET scan negative pulmonary nodule is generally considered to have a low likelihood of being malignant, but it is not a definitive exclusion of cancer 1. As a precautionary measure, it is recommended to follow up with a non-contrast CT scan of the chest in 3-6 months to monitor the nodule's size and characteristics.

Key Considerations

  • If the nodule is larger than 8mm, a follow-up CT scan should be done in 3 months 1.
  • For nodules smaller than 8mm, a follow-up CT scan can be done in 6-12 months.
  • Additionally, if the patient has a history of smoking or other risk factors for lung cancer, a more thorough evaluation, including a contrast-enhanced CT scan or a biopsy, may be necessary 1.
  • It is also recommended to consider the patient's overall clinical presentation, including symptoms and medical history, when determining the best course of action 1.

False-Negative Results

  • False-negative results on PET scan can occur in patients with less metabolically active tumors, including lepidic-predominant adenocarcinomas, mucinous adenocarcinomas, and carcinoid tumors 1.
  • False-positive results on PET scan can also occur, often due to infections or inflammatory conditions, including endemic mycoses, TB, rheumatoid nodules, and sarcoidosis 1.

From the Research

Significance of a Negative PET Scan Result

A negative Positron Emission Tomography (PET) scan result for a pulmonary nodule does not entirely rule out the possibility of malignancy.

  • The study by 2 found that 18.2% of initially PET-negative solid pulmonary nodules developed subsequent malignancy at an average time of 37.6 months.
  • Another study by 3 reported that cancer was diagnosed in 22.4% of the PET-negative subgroup, highlighting the need for continued follow-up.
  • The research by 4 and 5 demonstrated the diagnostic value of PET/CT in differentiating benign from malignant solitary pulmonary nodules, but also acknowledged the limitations of a negative PET scan result.

Implications of a Negative PET Scan Result

A negative PET scan result should not be considered a surrogate for tissue diagnosis in the case of non-FDG avid solitary pulmonary nodules.

  • The study by 2 emphasized the continued need for follow-up of initially PET-negative nodules beyond the 2 years currently suggested in popular guidelines.
  • The research by 3 supported the current surveillance practice of continuing to follow LungRADS-4/PET-negative patients as LungRADS-4 patients, given the high cancer risk despite a lack of activity on PET.
  • The study by 6 showed that PET/CT can improve stratification of cancer patients with indeterminate pulmonary nodules, but a substantial number of patients considered at low and intermediate pretest likelihood of malignancy with histology-proven lung malignancy showed abnormal PET/CT findings.

Clinical Considerations

Clinical variables such as nodule location, size, chronic obstructive pulmonary disease, family history of lung cancer, pack-years, and number of years quit in former smokers were not significantly associated with greater cancer risk among the PET-negative subgroup 3.

  • The study by 5 found that a negative PET scan is associated with only a 4.7% risk of malignancy, but this risk increases with the patient's age and the size of the nodule.
  • The research by 4 and 6 highlighted the importance of considering pretest probability of malignancy and the role of 18F-FDG PET/CT in characterizing indeterminate lung nodules.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Diagnostic value of PET/CT in differentiating benign from malignant solitary pulmonary nodules.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2013

Research

Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1996

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.